Defining the role of novel β-lactam agents that target carbapenem-resistant gram-negative organisms

Pranita Tamma, Alice J. Hsu

Research output: Contribution to journalReview article

Abstract

With the current carbapenem-resistant organism crisis, conventional approaches to optimizing pharmacokinetic-pharmacodynamic parameters are frequently inadequate, and traditional salvage agents (eg, colistin, tigecycline, etc) confer high toxicity and/or have low efficacy. However, several β-lactam agents with activity against carbapenem-resistant organisms were approved recently by the US Food and Drug Administration, and more are anticipated to be approved in the near future. The primary goal of this review is to assist infectious disease practitioners with preferentially selecting 1 agent over another when treating patients infected with a carbapenem-resistant organism. However, resistance to some of these antibiotics has already developed. Antibiotic stewardship programs can ensure that they are reserved for situations in which other options are lacking and are paramount for the survival of these agents.

Original languageEnglish (US)
Pages (from-to)251-260
Number of pages10
JournalJournal of the Pediatric Infectious Diseases Society
Volume8
Issue number3
DOIs
StatePublished - Jan 1 2019

Fingerprint

Lactams
Carbapenems
Anti-Bacterial Agents
Colistin
United States Food and Drug Administration
Communicable Diseases
Pharmacokinetics
Survival

Keywords

  • Aztreonam-avibactam
  • Cefiderocol
  • Ceftazidime-avibactam
  • Ceftolozane-tazobactam
  • Imipenem-cilastatin-relebactam
  • Meropenem-vaborbactam

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Infectious Diseases

Cite this

Defining the role of novel β-lactam agents that target carbapenem-resistant gram-negative organisms. / Tamma, Pranita; Hsu, Alice J.

In: Journal of the Pediatric Infectious Diseases Society, Vol. 8, No. 3, 01.01.2019, p. 251-260.

Research output: Contribution to journalReview article

@article{25815a29fd004f639e734a645ebf8a4a,
title = "Defining the role of novel β-lactam agents that target carbapenem-resistant gram-negative organisms",
abstract = "With the current carbapenem-resistant organism crisis, conventional approaches to optimizing pharmacokinetic-pharmacodynamic parameters are frequently inadequate, and traditional salvage agents (eg, colistin, tigecycline, etc) confer high toxicity and/or have low efficacy. However, several β-lactam agents with activity against carbapenem-resistant organisms were approved recently by the US Food and Drug Administration, and more are anticipated to be approved in the near future. The primary goal of this review is to assist infectious disease practitioners with preferentially selecting 1 agent over another when treating patients infected with a carbapenem-resistant organism. However, resistance to some of these antibiotics has already developed. Antibiotic stewardship programs can ensure that they are reserved for situations in which other options are lacking and are paramount for the survival of these agents.",
keywords = "Aztreonam-avibactam, Cefiderocol, Ceftazidime-avibactam, Ceftolozane-tazobactam, Imipenem-cilastatin-relebactam, Meropenem-vaborbactam",
author = "Pranita Tamma and Hsu, {Alice J.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1093/jpids/piz002",
language = "English (US)",
volume = "8",
pages = "251--260",
journal = "Journal of the Pediatric Infectious Diseases Society",
issn = "2048-7207",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Defining the role of novel β-lactam agents that target carbapenem-resistant gram-negative organisms

AU - Tamma, Pranita

AU - Hsu, Alice J.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - With the current carbapenem-resistant organism crisis, conventional approaches to optimizing pharmacokinetic-pharmacodynamic parameters are frequently inadequate, and traditional salvage agents (eg, colistin, tigecycline, etc) confer high toxicity and/or have low efficacy. However, several β-lactam agents with activity against carbapenem-resistant organisms were approved recently by the US Food and Drug Administration, and more are anticipated to be approved in the near future. The primary goal of this review is to assist infectious disease practitioners with preferentially selecting 1 agent over another when treating patients infected with a carbapenem-resistant organism. However, resistance to some of these antibiotics has already developed. Antibiotic stewardship programs can ensure that they are reserved for situations in which other options are lacking and are paramount for the survival of these agents.

AB - With the current carbapenem-resistant organism crisis, conventional approaches to optimizing pharmacokinetic-pharmacodynamic parameters are frequently inadequate, and traditional salvage agents (eg, colistin, tigecycline, etc) confer high toxicity and/or have low efficacy. However, several β-lactam agents with activity against carbapenem-resistant organisms were approved recently by the US Food and Drug Administration, and more are anticipated to be approved in the near future. The primary goal of this review is to assist infectious disease practitioners with preferentially selecting 1 agent over another when treating patients infected with a carbapenem-resistant organism. However, resistance to some of these antibiotics has already developed. Antibiotic stewardship programs can ensure that they are reserved for situations in which other options are lacking and are paramount for the survival of these agents.

KW - Aztreonam-avibactam

KW - Cefiderocol

KW - Ceftazidime-avibactam

KW - Ceftolozane-tazobactam

KW - Imipenem-cilastatin-relebactam

KW - Meropenem-vaborbactam

UR - http://www.scopus.com/inward/record.url?scp=85070683518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070683518&partnerID=8YFLogxK

U2 - 10.1093/jpids/piz002

DO - 10.1093/jpids/piz002

M3 - Review article

VL - 8

SP - 251

EP - 260

JO - Journal of the Pediatric Infectious Diseases Society

JF - Journal of the Pediatric Infectious Diseases Society

SN - 2048-7207

IS - 3

ER -